Skip to content
MARKETS / NASDAQ / ABSI
NASDAQ · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · SMALL CAP

Absci Corp. ABSI

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.8M
▼ 38.2% YoY
$-115.2M
$-94.0M
In brief

What this company does

We are a clinical-stage biopharmaceutical company using an AI-native approach to develop differentiated antibody therapeutics. Our integrated drug creation platform combines Origin-1, our generative design model, with rapid validation using our lab-in-the-loop. Our lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval. We have dosed the first three single ascending dose cohorts with a favorable safety profile to date. We plan to initiate a Phase 2 clinical trial of ABS-201 in endometriosis, a chronic condition estimated to affect approximately 10% of women of reproductive age worldwide. Our Integrated Drug Creation platform is the engine of our AI-native approach, allowing us to design anti-body based therapeutics that target underexplored biological mechanisms.

Written from the business description in Absci Corporation's annual report to the U.S. Securities and Exchange Commission, filed 24 March 2026. Every sentence was checked against that document before publication.

Growth
USD 2.8M
Revenue, FY2025 · full 6-year series below
Revenue $M Net income $M
FY2025 · Revenue 2.8 · Net income -115.2
-40M-80M202020212022202320242025
Compound annual growth
−14.8%
−7.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −7.4% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−4114 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -4297.0% · Net -4113.7%
-2000%-4000%202020212022202320242025
ROE
FY2025 · ROE -62.5%
-20%-40%-60%202020212022202320242025

Each USD of equity lost 63 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -94.0
-40M-80M202020212022202320242025

Total assetsUSD 216.3M
EquityUSD 189.4M
CashUSD 20.0M
Current ratio6.57×

Equity funds 88% of total assets.

The 6-year record
6 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020
Revenue $B0.00.00.00.00.00.0
Operating income $B−0.1−0.1−0.1−0.1−0.1−0.0
EBITDA $B−0.1−0.1−0.1−0.1−0.1−0.0
Income tax $B0.00.00.0−0.0−0.00.0
Net income $B−0.1−0.1−0.1−0.1−0.1−0.0
Free cash flow $B−0.1−0.1−0.1−0.1−0.1−0.0
EPS, diluted $−0.84−0.94−1.20−1.15−2.08−3.19
Dividend / sh $······
Payout %······
ROE %−62.5−58.0−49.1−32.8−73.0·
Shares out B·0.120.090.090.090.02

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 24 reconciliationsAUDITED

Reconciled in 6 of 19 fiscal years. 52 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityServices-Commercial Physical & Biological Research
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2020

Share this section

Download image